MedPath

Zosuquidar

Generic Name
Zosuquidar
Drug Type
Small Molecule
Chemical Formula
C32H31F2N3O2
CAS Number
167354-41-8
Unique Ingredient Identifier
AB5K82X98Y
Background

Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.

Indication

Investigated for use/treatment in leukemia (myeloid) and myelodysplastic syndrome.

Clinical Trials
Related News

A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

Phase 1
Completed
Conditions
Leukemia, Myeloid
First Posted Date
2005-10-06
Last Posted Date
2008-04-01
Lead Sponsor
Kanisa Pharmaceuticals
Target Recruit Count
55
Registration Number
NCT00233909

Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)

Phase 1
Completed
Conditions
Leukemia, Myeloid
First Posted Date
2005-08-11
Last Posted Date
2008-04-01
Lead Sponsor
Kanisa Pharmaceuticals
Target Recruit Count
100
Registration Number
NCT00129168

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

Phase 3
Completed
Conditions
Leukemia
Myelodysplastic Syndromes
Interventions
Biological: filgrastim
Biological: sargramostim
Drug: Placebo
First Posted Date
2003-01-27
Last Posted Date
2023-07-05
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
449
Registration Number
NCT00046930
Locations
🇺🇸

Evanston Northwestern Health Care - Evanston Hospital, Evanston, Illinois, United States

🇺🇸

CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States

🇺🇸

Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States

and more 88 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy